Solaris Asset Management LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 135.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,535 shares of the biopharmaceutical company’s stock after purchasing an additional 8,925 shares during the quarter. Solaris Asset Management LLC’s holdings in Pfizer were worth $563,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Mckinley Capital Management LLC Delaware acquired a new stake in Pfizer in the second quarter worth $103,000. Herndon Capital Management LLC acquired a new stake in Pfizer in the second quarter worth $120,000. Americafirst Capital Management LLC acquired a new stake in Pfizer in the third quarter worth $127,000. Private Vista LLC increased its position in Pfizer by 2,277.3% in the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 190,933 shares during the period. Finally, Lipe & Dalton increased its position in Pfizer by 6.9% in the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 300 shares during the period. Hedge funds and other institutional investors own 71.41% of the company’s stock.
In other Pfizer news, insider Charles H. Hill sold 42,393 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mikael Dolsten sold 69,699 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $36.59, for a total value of $2,550,286.41. Following the sale, the insider now owns 120,784 shares of the company’s stock, valued at $4,419,486.56. The disclosure for this sale can be found here. Insiders sold a total of 185,464 shares of company stock valued at $6,767,939 in the last quarter. 0.06% of the stock is currently owned by corporate insiders.
Pfizer Inc. (NYSE PFE) opened at $36.75 on Wednesday. Pfizer Inc. has a 52 week low of $31.67 and a 52 week high of $39.43. The firm has a market capitalization of $218,770.00, a PE ratio of 21.00, a P/E/G ratio of 2.07 and a beta of 0.91. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The business had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter last year, the business posted $0.47 earnings per share. The company’s quarterly revenue was up .6% on a year-over-year basis. equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer announced that its Board of Directors has approved a share buyback program on Monday, December 18th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.
The business also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were given a $0.34 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend was Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.70%. Pfizer’s dividend payout ratio (DPR) is 77.71%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.